Serum levels of ILs and RAS components at baseline and post-treatment in placebo and vitD treated groups
| Serum levels of ILs and RAS components | Baseline vs. placebo treatment | Baseline vs. vitD treatment | Change from baseline vitD treated vs. placebo treated | |
|---|---|---|---|---|
| IL-6 (pg/mL) | Baseline Post-treatment | 19.9 ± 5.3 vs. 17.6 ± 5.8 | 27.7 ± 8.8 vs. 35.1 ± 21.0 | 7.4 ± 22.4 vs. −2.2 ± 4.1 |
| IL-8 (pg/mL) | Baseline Post-treatment | 17.9 ± 5.0 vs. 17.4 ± 4.0 | 20.9 ± 3.4 vs. 30.8 ± 16.3 | 9.8 ± 13.9 vs. −0.5 ± 6.1 |
| IL-1B (pg/mL) | Baseline Post-treatment | 6.3 ± 1.2 vs. 7.5 ± 1.4 | 7.2 ± 0.8 vs. 5.5 ± 0.4 | −1.7 ± 0.4 vs. 1.2 ± 0.4 |
| TNF-α (pg/mL) | Baseline Post-treatment | 12.3 ± 2.4 vs. 12.7 ± 3.7 | 12.6 ± 1.7 vs. 9.0 ± 3.1 | −3.6 ± 3.0 vs. 0.3 ± 3.1 |
| IL-10 (pg/mL) | Baseline Post-treatment | 29.2 ± 3.8 vs. 31.4 ± 7.2 | 35.6 ± 7.1 vs. 63.7 ± 35.9 | 28.1 ± 35.5 vs. 2.2 ± 6.0 |
| Ang-(1-7) (pg/mL) | Baseline Post-treatment | 851.2 ± 130.8 vs. 1014.4 ± 170.3 | 645.3 ± 68.5 vs. 977.9 ± 190.1 | 332.6 ± 148.2 vs. 163.1 ± 55.7 |
| Ang-II (pg/mL) | Baseline Post-treatment | 209.0 ± 43.9 vs. 81.0 ± 21.3 | 132.2 ± 24.2 vs. 86.9 ± 27.5 | −45.2 ± 19.5 vs. −128.0 ± 26.0 |
| Ang-(1-7)/Ang-2 | Baseline Post-treatment | 2.5 ± 0.3 vs. 8.6 ± 2.3 | 5.2 ± 1.2 vs. 17.7 ± 4.7 | 12.5 ± 3.7 vs. 6.0 ± 2.2 |
Changes from baseline. The results are shown as mean ± standard error mean (SEM). * P < 0.05; ** P < 0.01
